Yale University

University of Pittsburgh

The University of Chicago

University of Illinois

University of Connecticut

Instituto Nacional De Enfermedades Respiratorias Ismael Cosio Villegas—d.f.

Naftali Kaminski

Jose David Herazo-Maya

Kevin Gibson

Imre Noth

Guoying Yu

Argyrios Tzouvelekis

Joe G N Garcia

Yong Huang

Tim D Oury

Raman Bahal

Farida Ahangari

Carlos Fernandez-Hernando

Bernadette R Gochuico

Thomas J Richards

Laura Voeghtly

Ivan Rosas

Kazuhisa Konishi

Moises Selman

Jan Johannes Enghild

In one aspect, the present disclosure provides a microRNA-33 (miR-33) inhibitor comprising a peptide nucleic acid covalently bound to a pH low insertion peptide. In another aspect, the present disclosure provides a method of treating pulmonary fibrosis in a subject, the method comprising administering to the subject a therapeutically effective amount of the miR-33 inhibitor. In some embodiments, the pulmonary fibrosis is idiopathic pulmonary fibrosis.

MicroRNA-33 inhibitors and use thereof in the treatment of pulmonary fibrosis

The present invention includes a method of preventing and/or treating a fibrotic lung disease in a subject. In certain embodiments, the method comprises administering to the subject a thyroid receptor &#x3b2;-agonist. The invention further comprises compositions useful within the invention, as well as kits comprising compositions useful within the invention.

Compositions and methods of treating or preventing fibrotic lung diseases

Disclosed are methods and kits for evaluating predicting whether an individual IPF has slowly or rapidly progressive IPF.

Biomarkers for assessing idiopathic pulmonary fibrosis

The clinical course of idiopathic pulmonary fibrosis (IPF) is difficult to predict. Described herein is a peripheral blood 52-gene expression signature useful to improve outcome prediction in IPF.

52-gene signature in peripheral blood identifies a genomic profile associated with increased risk of mortality and poor disease outcomes in idiopathic pulmonary fibrosis

The invention includes a method of preventing or treating a fibrotic lung disease in a subject, comprising administering to the subject a thyroid hormone by inhalation and/or aerosolization. The invention further comprises compositions and kits comprising compositions useful within the invention.

Methods of treating or preventing fibrotic lung diseases

Disclosed are methods are kits for evaluating predicting whether an individual IPF has slowly or rapidly progressive IPF.

The present invention relates to the discovery that of a panel of serum or plasma markers may be used to diagnose Idiopathic Pulmonary Fibrosis ('IPF') and distinguish this condition from other lung ailments. It further relates to the identification of markers associated with IPF disease progression.

Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation

A method is provided along with related reagent kits for aiding the diagnosis of IPF or other interstitial lung diseases, as well as for potential monitoring of disease progression or therapeutic response to treatment.

MMP activation peptide detection in biological samples

Growing community of inventors

New Haven, CT, United States of America

Naftali Kaminski